AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
debrisoquine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| quinoline derivatives | 788 | 1131-64-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 20 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 29 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 12 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 24.46 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | -1.029 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 0.420 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 8.091 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 3.715 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 45.520 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 62.830 | % | High | 1 |
| herg | hERG pIC50 | 4.434 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 4.305 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 8.375 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 56.750 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,AKT1,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK1,CDK4,CDK5,CDK9,CHEK1,CSF1R,DDR1,DYRK1B,EIF2AK3,EPHA2,EPHB4,ERBB2,FLT3,GRK2,GSK3B,IKBKB,ITK,JAK1,JAK2,JAK3,KIT,MAP2K1,MAP2K6,MAP3K1,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MARK4,MELK,MET,MTOR,NTRK2,PAK4,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ULK2,ZAP70 | 72 | |||
| kinase-selectivity-class | AXL,GRK2,PDK4 | 3 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 1.330 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 23.335 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 62.400 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 0.348 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 34.940 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 35.156 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 79.400 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 66.150 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 704.693 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 1, 1965 | YEAR INTRODUCED |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C02CC04 | CARDIOVASCULAR SYSTEM ANTIHYPERTENSIVES ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING Guanidine derivatives |
| MeSH PA | D000959 | Antihypertensive Agents |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D013565 | Sympatholytics |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018663 | Adrenergic Agents |
| CHEBI has role | CHEBI:35674 | antihypertensive agent |
| CHEBI has role | CHEBI:37962 | adrenergic agent |
| CHEBI has role | CHEBI:66991 | sympatholytic agent |
| CHEBI has role | CHEBI:77746 | human metabolite |
Related Drugs by ATC class:
C02CC Guanidine derivatives 6 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 10.82 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Amine oxidase [flavin-containing] B | Enzyme | WOMBAT-PK | |||||||
| Amine oxidase [flavin-containing] A | Enzyme | WOMBAT-PK | |||||||
| Transmembrane protease serine 2 | Enzyme | IC50 | 4.64 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| N0000166976 | NUI |
| D03664 | KEGG_DRUG |
| 3118 | RXNORM |
| C0011082 | UMLSCUI |
| CHEBI:34665 | CHEBI |
| CHEMBL169901 | ChEMBL_ID |
| DB04840 | DRUGBANK_ID |
| 581-88-4 | SECONDARY_CAS_RN |
| 2966 | PUBCHEM_CID |
| 003838 | NDDF |
| 350602000 | SNOMEDCT_US |
| 396010003 | SNOMEDCT_US |
| D003647 | MESH_DESCRIPTOR_UI |
| CHEMBL1593558 | ChEMBL_ID |
| 1968 | INN_ID |
| X31CDK040E | UNII |
| X31CDK040E | INXIGHT DRUGS |
Pharmaceutical products:
None